↓ Skip to main content

American Association for Cancer Research

Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway

Overview of attention for article published in Molecular Cancer Therapeutics, July 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

patent
73 patents

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
57 Mendeley
Title
Identification and preclinical characterization of AZ-23, a novel, selective, and orally bioavailable inhibitor of the Trk kinase pathway
Published in
Molecular Cancer Therapeutics, July 2009
DOI 10.1158/1535-7163.mct-09-0036
Pubmed ID
Authors

Kenneth Thress, Terry MacIntyre, Haiyun Wang, Dave Whitston, Zhong-Ying Liu, Ethan Hoffmann, Tao Wang, Jeffrey L. Brown, Kevin Webster, Charles Omer, Peter E. Zage, Lizhi Zeng, Patrick A. Zweidler-McKay

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Japan 1 2%
United States 1 2%
Unknown 54 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 23 40%
Other 9 16%
Student > Master 7 12%
Student > Doctoral Student 4 7%
Student > Ph. D. Student 4 7%
Other 6 11%
Unknown 4 7%
Readers by discipline Count As %
Agricultural and Biological Sciences 20 35%
Medicine and Dentistry 11 19%
Chemistry 9 16%
Pharmacology, Toxicology and Pharmaceutical Science 5 9%
Biochemistry, Genetics and Molecular Biology 4 7%
Other 2 4%
Unknown 6 11%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2023.
All research outputs
#3,907,044
of 26,017,215 outputs
Outputs from Molecular Cancer Therapeutics
#631
of 4,105 outputs
Outputs of similar age
#14,738
of 126,341 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#7
of 73 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,105 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.9. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 126,341 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.